
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Researchers have developed an algorithm that uses traditional risk factors to predict whether a newborn will develop obesity as a child.






